Loading...
•
Dec 31, 2022
Ionis Q4 2022 Earnings Report
Ionis Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Ionis Pharmaceuticals reported Q4 2022 total revenue of $152 million and a net loss of $52 million. The company's cash, cash equivalents, and short-term investments amounted to $1.987 billion. The company submitted the eplontersen NDA in the U.S.
2022 revenue was in line with expectations, reflecting revenue from numerous diverse sources.
2022 operating expenses increased as planned compared to the prior year, reflecting investments in pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen
Further strengthened financial position with royalty monetization and sale and leaseback transactions worth up to $1.5 billion, including more than $700 million already received
Submitted the eplontersen NDA in the U.S. for patients with polyneuropathy caused by hereditary TTR amyloidosis
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.comCollaborative agreements Revenue
CapyFin.com Forward Guidance
The Company’s 2023 guidance reflects its ability to earn substantial revenue from its commercial portfolio and partnered programs. It also reflects the Company’s commitment to investing in advancing its rich late-stage pipeline and preparing to commercialize its near-term commercial opportunities, eplontersen, olezarsen and donidalorsen, while maintaining a healthy balance sheet to continue investing for future growth.
Positive Outlook
- Revenue >$575 million
- Operating expenses on a non-GAAP basis ~$970 - $995 million
- Net operating loss on a non-GAAP basis <$425 million
- Cash, cash equivalents and short-term investments ~$2.0 billion
- Continue to advance our innovative pipeline and achieve commercial readiness for eplontersen, olezarsen and donidalorsen.
Revenue & Expenses
Visualization of income flow from segment revenue to net income